Moxifloxacin
drugOn this page
Also known as AveloxAvelox i.v.Avelox ivMoxifloxacineMoxifloxacinoZimoxinMoxifloxinmotifloxacinMoxiflox
Summary
Moxifloxacin (CHEMBL32) is an approved small-molecule antibacterial drug (ATC J01MA14); indicated across 81 conditions including eye infectious disorder and bacterial infectious disease.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: J01MA14 (+1 more)
- Indications: 81 conditions
- Clinical trials: 434
- Chemistry: C21H24FN3O4
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL32 |
| Name | Moxifloxacin |
| Type | Small molecule |
| Max phase | 4 |
| ChEBI | CHEBI:63611 |
| ATC | J01MA14, S01AE07 |
| Molecular formula | C21H24FN3O4 |
| InChIKey | FABPRXSRWADJSP-MEDUHNTESA-N |
SMILES: [H][C@@]12CCCN[C@]1([H])CN(c1c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c1OC)C2
ChEBI definition: A quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.
Pharmacological roles (ChEBI): antibacterial drug.
Also known as: Avelox, Avelox i.v., Avelox iv, Moxifloxacin, Moxifloxacine, Moxifloxacino, Zimoxin, moxifloxacin, Moxifloxin, motifloxacin, MOXIFLOXACINE, MOXIFLOXACIN
Parent form; salt/anhydrous children: CHEMBL1200735, CHEMBL2326947, CHEMBL3765320
Patent coverage: 8,441 distinct patent families (30,176 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 29,739 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 9 (assay-derived). Sample: Sodium channel protein type 5 subunit alpha, DNA gyrase, Muscarinic acetylcholine receptor M1, Kappa-type opioid receptor, Voltage-gated inwardly rectifying potassium channel KCNH2, DNA gyrase, DNA gyrase subunit A/DNA gyrase subunit B, DNA topoisomerase 4 subunit A, DNA gyrase subunit A.
Bioactivity
ChEMBL activities: 13 potent at pChembl ≥ 5 of 27 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| P0AES4 | 6.52 | IC50 | 300 | nM | CHEMBL_ACT_1695505 |
| OPRK1 | 6.5 | AC50 | 320 | nM | CHEMBL_ACT_25130059 |
| P0C1U9 | 6.1 | IC50 | 800 | nM | CHEMBL_ACT_1689637 |
| P0C1U9 | 6.1 | IC50 | 800 | nM | CHEMBL_ACT_1695521 |
| P0AES4 | 5.6 | IC50 | 2500 | nM | CHEMBL_ACT_3570428 |
| P9WG45 | 5.22 | IC50 | 6000 | nM | CHEMBL_ACT_3570036 |
| P0A0K8 | 5.17 | IC50 | 6800 | nM | CHEMBL_ACT_24921767 |
| P0A0K8 | 5.11 | IC50 | 7700 | nM | CHEMBL_ACT_6184805 |
| P9WG45 | 5.09 | IC50 | 8100 | nM | CHEMBL_ACT_15112914 |
| CHRM1 | 5.09 | AC50 | 8200 | nM | CHEMBL_ACT_25210789 |
| P9WG47 | 5.04 | IC50 | 9200 | nM | CHEMBL_ACT_3551850 |
| P9WG45 | 5 | IC50 | 10000 | nM | CHEMBL_ACT_15105474 |
| P9WG45 | 5 | IC50 | 10000 | nM | CHEMBL_ACT_24921901 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
81 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| eye infectious disorder | 4 | MONDO:0043885 | EFO:1001888 |
| bacterial infectious disease | 4 | MONDO:0005113 | EFO:0000771 |
| chronic obstructive pulmonary disease | 3 | MONDO:0005002 | EFO:0000341 |
| chronic bronchitis | 3 | MONDO:0005607 | EFO:0006505 |
| bacterial conjunctivitis | 3 | MONDO:0006668 | EFO:1000829 |
| pneumonia | 3 | MONDO:0005249 | EFO:0003106 |
| bacterial pneumonia | 3 | MONDO:0004652 | EFO:1001272 |
| abscess | 3 | MONDO:0005227 | EFO:0003030 |
| cellulitis | 3 | MONDO:0005230 | EFO:0003035 |
| sinusitis | 3 | MONDO:0005961 | EFO:0007486 |
| pulmonary tuberculosis | 3 | MONDO:0006052 | EFO:1000049 |
| acute cholecystitis | 3 | MONDO:0043994 | EFO:1001289 |
| pelvic inflammatory disease | 3 | MONDO:0000922 | EFO:1001388 |
| influenza | 3 | MONDO:0005812 | EFO:0007328 |
| breast neoplasm | 3 | MONDO:0021100 | MONDO:0007254 |
| endophthalmitis | 3 | MONDO:0016047 | MONDO:0016047 |
| skin disorder | 3 | MONDO:0005093 | EFO:0000701 |
| meningitis | 3 | MONDO:0021108 | MONDO:0021108 |
| Acanthamoeba keratitis | 3 | MONDO:0005629 | EFO:0007126 |
| cataract | 3 | MONDO:0005129 | MONDO:0005129 |
| tuberculosis | 3 | MONDO:0018076 | MONDO:0018076 |
| severe acute respiratory syndrome | 3 | MONDO:0005091 | MONDO:0100096 |
| Helicobacter pylori infectious disease | 3 | MONDO:0006781 | EFO:1000961 |
| keratitis | 3 | MONDO:0003085 | EFO:0009449 |
| otitis media | 3 | MONDO:0005441 | MONDO:0024330 |
| lung disorder | 2 | MONDO:0005275 | EFO:0003818 |
| neoplasm | 2 | MONDO:0005070 | EFO:0000616 |
| multidrug-resistant tuberculosis | 2 | MONDO:0005861 | EFO:0007381 |
| cholangitis | 2 | MONDO:0004789 | HP:0030151 |
| Parkinson disease | 2 | MONDO:0005180 | MONDO:0005180 |
| meningeal tuberculosis | 2 | MONDO:0006042 | EFO:1000039 |
| corneal ulcer | 2 | MONDO:0004577 | MONDO:0004577 |
| diabetes mellitus | 1 | MONDO:0005015 | EFO:0000400 |
| acute coronary syndrome | 1 | MONDO:0005542 | EFO:0005672 |
| hepatitis C virus infection | 1 | MONDO:0005231 | EFO:0003047 |
| renal cell carcinoma | 1 | MONDO:0005086 | EFO:0000681 |
| rheumatoid arthritis | 1 | MONDO:0008383 | EFO:0000685 |
| HIV infectious disease | 1 | MONDO:0005109 | EFO:0000764 |
| fibromyalgia | 1 | MONDO:0005546 | EFO:0005687 |
| Plasmodium vivax malaria | 1 | MONDO:0005921 | EFO:0007445 |
| restless legs syndrome | 1 | MONDO:0005391 | EFO:0004270 |
| constipation disorder | 1 | MONDO:0002203 | HP:0002019 |
| epilepsy | 1 | MONDO:0005027 | EFO:0000474 |
| erectile dysfunction | 1 | MONDO:0005362 | EFO:0004234 |
| lymphoma | 1 | MONDO:0005062 | EFO:0000574 |
| hypertensive disorder | 1 | MONDO:0005044 | EFO:0000537 |
| AIDS | 1 | MONDO:0012268 | EFO:0000765 |
| coronary artery disorder | 1 | MONDO:0005010 | EFO:0001645 |
| anemia | 1 | MONDO:0002280 | EFO:0004272 |
| schizoaffective disorder | 1 | MONDO:0005487 | EFO:0005411 |
| congestive heart failure | 1 | MONDO:0005009 | EFO:0000373 |
| dyspepsia | 1 | MONDO:0002268 | EFO:0008533 |
| lice infestation | 1 | MONDO:0003472 | MONDO:0003472 |
| orthostatic hypotension | 1 | MONDO:0005469 | EFO:0005252 |
| respiratory tract infectious disorder | 1 | MONDO:0024355 | MONDO:0024355 |
| immune system disorder | 1 | MONDO:0005046 | EFO:0000540 |
| hypoglycemia | 1 | MONDO:0004946 | HP:0001943 |
| Alzheimer disease | 1 | MONDO:0004975 | MONDO:0004975 |
| amyotrophic lateral sclerosis | 1 | MONDO:0004976 | MONDO:0004976 |
| asthma | 1 | MONDO:0004979 | MONDO:0004979 |
| type 2 diabetes mellitus | 1 | MONDO:0005148 | MONDO:0005148 |
| phenylketonuria | 1 | MONDO:0009861 | MONDO:0009861 |
| obesity disorder | 1 | MONDO:0011122 | EFO:0001073 |
| metabolic dysfunction-associated steatotic liver disease | 1 | MONDO:0013209 | EFO:0003095 |
| myocardial ischemia | 1 | MONDO:0024644 | EFO:1001375 |
| systemic lupus erythematosus | 1 | MONDO:0007915 | MONDO:0007915 |
| cystic fibrosis | 1 | MONDO:0009061 | MONDO:0009061 |
| osteomyelitis | 0 | MONDO:0005246 | EFO:0003102 |
13 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 434.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1 | 288 |
| PHASE3 | 44 |
| PHASE4 | 34 |
| PHASE2 | 28 |
| Not specified | 28 |
| PHASE2/PHASE3 | 9 |
| PHASE1/PHASE2 | 2 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05331664 | PHASE4 | RECRUITING | Dropless Pars Plana Vitrectomy Study |
| NCT05398679 | PHASE4 | RECRUITING | Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis |
| NCT00407017 | PHASE4 | COMPLETED | Therapeutic Variables in Cataract Surgery |
| NCT00464438 | PHASE4 | COMPLETED | A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis |
| NCT00564447 | PHASE4 | COMPLETED | Study of AzaSite (Azithromycin) Versus Vigamox in the Conjunctiva of Healthy Volunteers |
| NCT00581542 | PHASE4 | COMPLETED | Moxifloxacin vs. Polytrim for Conjunctivitis |
| NCT00752947 | PHASE4 | UNKNOWN | Efficacy and Safety Trial to Assess Moxifloxacin in Treating Community-Acquired Pneumonia (CAP) With Aspiration Factors |
| NCT00805558 | PHASE4 | COMPLETED | Comparison of Moxifloxacin With Ciprofloxacin/Metronidazole on Patients With Chronic Periodontitis |
| NCT00840580 | PHASE4 | COMPLETED | Effect on Wound Healing of Vigamox Versus Cravit |
| NCT00874887 | PHASE4 | COMPLETED | A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms |
| NCT00887276 | PHASE4 | TERMINATED | Study to Proof the Clinical and Bacteriological Non-inferiority of Ampicillin/Amoxicillin Versus Moxifloxacin in Hospitalized Patients With Non-severe Community-acquired Pneumonia |
| NCT00895089 | PHASE4 | COMPLETED | Moxifloxacin Versus Ceftriaxone in the Treatment of Primary Pyogenic Liver Abscess |
| NCT00924729 | PHASE4 | COMPLETED | Study of Ocular Penetration of Topically Administered Fluoroquinolones |
| NCT00952796 | PHASE4 | COMPLETED | A Comparative Study of Ampicillin/Sulbactam Versus Moxifloxacin in the Treatment of Complicated Intra-abdominal Infections |
| NCT01091493 | PHASE4 | COMPLETED | Antibiotic or Not in Non-purulent Exacerbations of COPD: a Trial of Security and Efficacy |
| NCT01296191 | PHASE4 | COMPLETED | Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification |
| NCT01296542 | PHASE4 | COMPLETED | A Comparison of Prophylactic Antibacterial Efficacy of Besivance vs. VIGAMOX Prior to Cataract Surgery |
| NCT01302951 | PHASE4 | COMPLETED | Penetration of Moxifloxacin Into Liver Tissue of Patients Undergoing Liver Resection. |
| NCT01329250 | PHASE4 | TERMINATED | Pharmacokinetics and Safety of Moxifloxacin |
| NCT01792700 | PHASE4 | COMPLETED | Long-term Follow up Helicobacter Pylori Reinfection Rate After Second-Line Treatment: Bismuth-Containing Quadruple Therapy Versus Moxifloxacin-Based Triple Therapy |
| NCT01799356 | PHASE4 | COMPLETED | Moxifloxacin Versus Ofloxacin Plus Metronidazole in Uncomplicated Pelvic Inflammatory Disease: Multicenter Randomized Controlled Trials |
| NCT01854710 | PHASE4 | COMPLETED | ADASUVE 2-dose Thorough QT/QTc Study |
| NCT01859702 | PHASE4 | COMPLETED | Pharmacokinetic Evaluation of Moxifloxacin in Vigadexa® in Aqueous Humor Samples Following Preoperative Antibiotic/Steroid Dosing in Cataract Surgery Patients |
| NCT01860703 | PHASE4 | COMPLETED | Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects |
| NCT02016157 | PHASE4 | COMPLETED | Moxifloxacin in Situ Gel to Treat Periodontal Pocket. |
| NCT02223702 | PHASE4 | COMPLETED | Alternative Antibiotic Regime in the Treatment of GAgP |
| NCT02515045 | PHASE4 | COMPLETED | Dropless vs. Standard Drops Contralateral Eye Study |
| NCT03363295 | PHASE4 | COMPLETED | Evaluation of Macular Changes After Intracameral Moxifloxacin for Prevention of Endophthalmitis |
| NCT03609099 | PHASE4 | UNKNOWN | Adequate Duration of Antibiotic Treatment in Community-acquired Pneumonia With High Risk Class and Adequate Initial Clinical Response |
| NCT03634852 | PHASE4 | COMPLETED | A Two Chemoprophylaxis Approaches After Phacoemulsification Surgery |
| NCT04403334 | PHASE4 | COMPLETED | Postoperative Safety Outcomes of Intraoperative Intracameral Preservative-Free Moxifloxacin Versus Levofloxacin |
| NCT05046132 | PHASE4 | COMPLETED | Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants |
| NCT05079854 | PHASE4 | UNKNOWN | Use Of Intracameral Moxifloxacin For Prophylaxis Of Open Globe Endophthalmitis |
| NCT06785090 | PHASE4 | COMPLETED | Effects of Bromfenac on Macular Thickness After Phacoemulsification Surgery |
| NCT03244072 | PHASE2/PHASE3 | NOT_YET_RECRUITING | Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery |
| NCT04310930 | PHASE2/PHASE3 | RECRUITING | Finding the Optimal Regimen for Mycobacterium Abscessus Treatment |
| NCT05454345 | PHASE3 | NOT_YET_RECRUITING | Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment |
| NCT05766267 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | Short-course Regimens for the Treatment of Pulmonary Tuberculosis |
| NCT05917340 | PHASE3 | NOT_YET_RECRUITING | Intensified Short Course Regimen for TBM in Adults |
| NCT06081361 | PHASE3 | ACTIVE_NOT_RECRUITING | Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: eye infectious disorder, bacterial infectious disease, chronic obstructive pulmonary disease, chronic bronchitis, bacterial conjunctivitis, pneumonia, bacterial pneumonia, abscess, cellulitis, sinusitis, pulmonary tuberculosis, acute cholecystitis, pelvic inflammatory disease, influenza, breast neoplasm, endophthalmitis, skin disorder, meningitis, Acanthamoeba keratitis, cataract, tuberculosis, severe acute respiratory syndrome, Helicobacter pylori infectious disease, keratitis, otitis media